Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVE2268 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AVE2268 | DRUG | - |
Inclusion Criteria: * Type 2 diabetes mellitus, as defined by the American Diabetes Association, for at least one year at the time of screening. * HbA1c measured at visit 1 in the range of ≥ 7.0 and \< 9.0 %. * Stable metformin treatment (dose ≥ 1.5g/day for at least 3 months prior to enrollment in...
AVE2268 is an investigational small molecule being developed for Type 2 Diabetes Mellitus. It is intended for patients whose diabetes is not adequately controlled by metformin treatment. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
AVE2268 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for the treatment of Type 2 Diabetes Mellitus.
AVE2268 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. The drug is being studied in patients with Type 2 Diabetes Mellitus who are not adequately controlled by metformin treatment.
AVE2268 has one completed Phase 2 clinical trial registered under NCT00361738. This was a dose-ranging study evaluating the drug in 317 patients with Type 2 Diabetes Mellitus not adequately controlled by metformin. The trial was conducted across multiple countries including Argentina, Australia, Belgium, Chile, Denmark, France, Germany, Italy, Netherlands, Poland, and South Africa.
AVE2268 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Type 2 Diabetes Mellitus. The drug has not completed the clinical trial process required for regulatory approval, and its safety and efficacy have not been established for commercial use.